Should I buy or sell BioAtla stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks .

What is BioAtla's stock price target for 2024?

5 Wall Street analysts have issued 12 month target prices for BioAtla's shares. Their BCAB share price targets range from $10.00 to $25.00. On average, they anticipate the company's share price to reach $14.80 in the next year. This suggests a possible upside of 980.3% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts .

How have BCAB shares performed in 2023?

BioAtla's stock was trading at $8.25 on January 1st, 2023. Since then, BCAB stock has decreased by 83.4% and is now trading at $1.37. View the best growth stocks for 2023 here .

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our BCAB earnings forecast .

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.07.

What ETF holds BioAtla's stock ?

Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.

When did BioAtla IPO?

(BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.

Who are BioAtla's major shareholders?

BioAtla's stock is owned by many different retail and institutional investors. Top institutional shareholders include Adage Capital Partners GP L.L.C. (3.76%), Vontobel Holding Ltd. (1.50%), Sectoral Asset Management Inc. (1.48%), Vivo Capital LLC (1.12%), Massachusetts Financial Services Co. MA (1.11%) and Northern Trust Corp (0.75%). Insiders that own company stock include Christian Vasquez , Cormorant Asset Management, Lp, Eric Sievers , Guy Levy , Jay M Phd Short , Lawrence Steinman , Richard A Waldron , Scott Andrew Smith and Sylvia Mcbrinn. View institutional ownership trends .

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

BioAtla Stock Price, News & Analysis (NASDAQ:BCAB)

$1.37

-0.40 (-22.60%)

(As of 12/4/2023 ET)

Compare

Today's Range: $1.35
▼
$1.78
50-Day Range: $1.27
▼
$1.98
52-Week Range: $1.24
▼
$10.83

Volume: 1.78 million shs
Average Volume: 501,843 shs
Market Capitalization: $65.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.80

BioAtla MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 980.3% Upside
$14.80 Price Target
Short Interest: Bearish
8.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.98
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$5,080 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.75) to ($2.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

343rd out of 952 stocks

Biological Products, Except Diagnostic Industry

55th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
BioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.80, BioAtla has a forecasted upside of 980.3% from its current price of $1.37.
Amount of Analyst Coverage
BioAtla has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.59% of the outstanding shares of BioAtla have been sold short.
Short Interest Ratio / Days to Cover
BioAtla has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
Change versus previous month
Short interest in BioAtla has recently increased by 0.98%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BioAtla does not currently pay a dividend.
Dividend Growth
BioAtla does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCAB.

3.9

News and Social Media Coverage

News Sentiment
BioAtla has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for BioAtla this week, compared to 1 article on an average week.
Search Interest
15 people have searched for BCAB on MarketBeat in the last 30 days.
MarketBeat Follows
66 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 187% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioAtla insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,080.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.38% of the stock of BioAtla is held by insiders.
Percentage Held by Institutions
71.67% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BioAtla are expected to grow in the coming year, from ($2.75) to ($2.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioAtla is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioAtla is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioAtla has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioAtla Stock (NASDAQ:BCAB)

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BCAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCAB Stock News Headlines

December 4, 2023 | msn.com

BCAB, DUNE and CDT among mid-day movers

November 30, 2023 | finance.yahoo.com

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 28, 2023 | finance.yahoo.com

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

November 12, 2023 | finance.yahoo.com

BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript

November 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB) and Silk Road Medical (SILK)

November 8, 2023 | morningstar.com

BioAtla Inc Ordinary Shares BCAB

November 7, 2023 | finance.yahoo.com

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 20, 2023 | finance.yahoo.com

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

October 17, 2023 | markets.businessinsider.com

Promising Outlook for BioAtla’s ADCs in NSCLC Treatment Bolsters Buy Rating

October 13, 2023 | markets.businessinsider.com

BioAtla Inc Registered Shs hosts conference call for investors

October 12, 2023 | finance.yahoo.com

BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award

September 25, 2023 | markets.businessinsider.com

Analyst Ratings for BioAtla

September 6, 2023 | finance.yahoo.com

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 3, 2023 | finance.yahoo.com

BioAtla to Participate in Upcoming Investor Conferences in August

August 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Exelixis (EXEL) and Steris (STE)

August 3, 2023 | msn.com

JP Morgan Maintains BioAtla (BCAB) Overweight Recommendation

August 3, 2023 | msn.com

JMP Securities Reiterates BioAtla (BCAB) Market Outperform Recommendation

August 3, 2023 | finance.yahoo.com

BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call Transcript

August 2, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on BioAtla (BCAB)

August 1, 2023 | finance.yahoo.com

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

July 25, 2023 | finance.yahoo.com

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

July 7, 2023 | finance.yahoo.com

With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners

July 6, 2023 | msn.com

BioAtla (BCAB) Price Target Increased by 9.33% to 16.73

June 26, 2023 | finance.yahoo.com

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

May 31, 2023 | finance.yahoo.com

BioAtla to Participate in the Jefferies Healthcare Conference

See More Headlines

Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCAB
CUSIP: N/A
CIK: 1826892
Web: www.bioatla.com
Phone: 858-558-0708
Fax: N/A
Employees: 66
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.80
High Stock Price Target: $25.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +980.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -89.27%
Return on Assets: -65.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.14
Quick Ratio: 4.14

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 262.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.79 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 47,940,000
Free Float: 43,919,000
Market Cap: $65.68 million
Optionable: Not Optionable
Beta: 0.69

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Jay M. Short Ph.D. (Age 65)
Co-Founder, CEO & Chairman
Comp: $1.06M
Mr. Richard A. Waldron (Age 69)
Senior VP & CFO
Comp: $617.62k
Dr. Eric L. Sievers M.D. (Age 59)
Chief Medical Officer
Comp: $608.18k
Mr. Christian J. Vasquez (Age 47)
Senior VP of Finance, Corporate Controller & Secretary
Comp: $408.75k
Lisa M. Pelton
Accounting Manager
Ms. Susie Melody
Senior Vice President of Human Resources
Dr. Cathy Chang Ph.D.
Senior Vice President of Research & Development
Dr. Gerhard Frey Ph.D.
Senior Vice President of Technology Development
Ms. Monica Sullivan
Senior Vice President of Intellectual Property & Contracts
Ms. Sheri Lydick
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCAB Stock Analysis - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings or view top-rated stocks.
What is BioAtla's stock price target for 2024?: 5 Wall Street analysts have issued 12 month target prices for BioAtla's shares. Their BCAB share price targets range from $10.00 to $25.00. On average, they anticipate the company's share price to reach $14.80 in the next year. This suggests a possible upside of 980.3% from the stock's current price.
View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts.
How have BCAB shares performed in 2023?: BioAtla's stock was trading at $8.25 on January 1st, 2023. Since then, BCAB stock has decreased by 83.4% and is now trading at $1.37.
View the best growth stocks for 2023 here.
When is BioAtla's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our BCAB earnings forecast.
How were BioAtla's earnings last quarter?: BioAtla, Inc. (NASDAQ:BCAB) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.07.

What ETF holds BioAtla's stock ?: Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.
When did BioAtla IPO?: (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.
Who are BioAtla's major shareholders?: BioAtla's stock is owned by many different retail and institutional investors. Top institutional shareholders include Adage Capital Partners GP L.L.C. (3.76%), Vontobel Holding Ltd. (1.50%), Sectoral Asset Management Inc. (1.48%), Vivo Capital LLC (1.12%), Massachusetts Financial Services Co. MA (1.11%) and Northern Trust Corp (0.75%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends.
How do I buy shares of BioAtla?: Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BCAB) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial